rabeprazole has been researched along with Sensitivity and Specificity in 25 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the optimal dosage of rabeprazole for proton-pump inhibitor (PPI) testing of gastroesophageal reflux disease (GERD) and to test the influence of cytochrome P450 (CYP) 2C19 polymorphism in a population with a high prevalence of people who metabolize PPI poorly." | 9.12 | Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. ( Chiu, HM; Lee, YC; Lin, JT; Wang, HP; Wu, MS, 2007) |
| "To study the acid exposure characteristic of the subtypes of non-erosive gastroesophageal reflux disease (NERD) and discuss the value of rabeprazole in its diagnosis." | 9.12 | [Oesophageal acid exposure test in non-erosive gastroesophageal reflux disease and the diagnostic value of rabeprazole]. ( Fan, YH; Lü, B; Zhan, LX; Zhang, L, 2007) |
| "Therapeutic trials with high-dose lansoprazole and omeprazole have been shown to be sensitive clinical tools for diagnosing patients with gastro-oesophageal reflux disease-related non-cardiac chest pain." | 9.11 | The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. ( Cui, H; Dickman, R; Emmons, S; Esquivel, RF; Fass, R; Hernández, D; Sewell, J, 2005) |
| "However, during the second week, GERD-related NCCP had a higher positive PPI test (n = 13, 81%) than non GERD-related NCCP (n = 7, 27%) (P = 0." | 6.74 | Comparison of one-week and two-week empirical trial with a high-dose rabeprazole in non-cardiac chest pain patients. ( Kim, JH; Kim, JJ; Rhee, JC; Rhee, PL; Sinn, DH; Son, HJ, 2009) |
| "The diagnosis of GERD was established on the presence of mucosal breaks at endoscopy and/or an abnormal esophageal 24-h pH test." | 6.72 | Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting. ( Aygalenq, P; Bonnot-Marlier, S; des Varannes, SB; Galmiche, JP; Le Rhun, M; Lequeux, Y; Masliah, C; Sacher-Huvelin, S; Vavasseur, F, 2006) |
| "To evaluate the optimal dosage of rabeprazole for proton-pump inhibitor (PPI) testing of gastroesophageal reflux disease (GERD) and to test the influence of cytochrome P450 (CYP) 2C19 polymorphism in a population with a high prevalence of people who metabolize PPI poorly." | 5.12 | Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. ( Chiu, HM; Lee, YC; Lin, JT; Wang, HP; Wu, MS, 2007) |
| "To study the acid exposure characteristic of the subtypes of non-erosive gastroesophageal reflux disease (NERD) and discuss the value of rabeprazole in its diagnosis." | 5.12 | [Oesophageal acid exposure test in non-erosive gastroesophageal reflux disease and the diagnostic value of rabeprazole]. ( Fan, YH; Lü, B; Zhan, LX; Zhang, L, 2007) |
| "Therapeutic trials with high-dose lansoprazole and omeprazole have been shown to be sensitive clinical tools for diagnosing patients with gastro-oesophageal reflux disease-related non-cardiac chest pain." | 5.11 | The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. ( Cui, H; Dickman, R; Emmons, S; Esquivel, RF; Fass, R; Hernández, D; Sewell, J, 2005) |
| "However, during the second week, GERD-related NCCP had a higher positive PPI test (n = 13, 81%) than non GERD-related NCCP (n = 7, 27%) (P = 0." | 2.74 | Comparison of one-week and two-week empirical trial with a high-dose rabeprazole in non-cardiac chest pain patients. ( Kim, JH; Kim, JJ; Rhee, JC; Rhee, PL; Sinn, DH; Son, HJ, 2009) |
| "The diagnosis of GERD was established on the presence of mucosal breaks at endoscopy and/or an abnormal esophageal 24-h pH test." | 2.72 | Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting. ( Aygalenq, P; Bonnot-Marlier, S; des Varannes, SB; Galmiche, JP; Le Rhun, M; Lequeux, Y; Masliah, C; Sacher-Huvelin, S; Vavasseur, F, 2006) |
| "In subjects with gastro-oesophageal reflux disease treated with a gastric antisecretory agent, the extent to which gastric acidity needs to be reduced to prevent pathological oesophageal acid exposure is not known." | 2.71 | Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro-oesophageal reflux disease treated with a proton pump inhibitor. ( Gardner, JD; Miner, PB; Robinson, M; Sloan, S, 2003) |
| "Rabeprazole is an effective proton pump inhibitor to treat acid-related diseases." | 1.48 | Stereoselective pharmacokinetics of (R)-(+)- and (S)-(-)-rabeprazole in human using chiral LC-MS/MS after administration of rabeprazole sodium enteric-coated tablet. ( Ding, L; Li, D; Li, TF; Shen, YW; Sun, LN; Wang, YQ; Ying, YW; Zhang, XH; Zhao, P, 2018) |
| "We examined 27 patients with hypochlorhydria or achlorhydria based on a predefined basal acid output (BAO) measurement of less than 5." | 1.39 | Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome. ( Metz, DC; Shah, P; Singh, MH; Yang, YX, 2013) |
| "Despite consensus recommendations, eosinophilic esophagitis (EoE) is commonly diagnosed upon esophageal eosinophilic infiltration (EEI; based on ≥ 15 eosinophils per high power field; eo/HPF)." | 1.37 | Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. ( Dueñas, C; Fernandez-Bermejo, M; Fernandez-Gonzalez, N; Ferrando-Lamana, L; Gonzalez-Nuñez, MA; Hernandez-Alonso, M; Mateos, JM; Molina-Infante, J; Quintana, EM; Ripoll, C, 2011) |
| "A stability-indicating thin layer chromatographic (TLC) method for determination of dexrabeprazole (DEX) and domperidone (DOM) in combined dosage form has been developed and validated." | 1.36 | Stability-indicating TLC-densitometric method for estimation of dexrabeprazole and domperidone in pharmaceutical dosage form. ( Chitlange, SS; Mulla, AI; Pawbake, GR; Wankhede, SB, 2010) |
| " The developed assay method was applied to a pharmacokinetic study in human volunteers." | 1.35 | Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. ( Bharathi, DV; Chatki, PK; Hotha, KK; Jagadeesh, B; Mullangi, R; Naidu, A; Thriveni, K, 2009) |
| "In order to evaluate the pharmacokinetic (PK) profile of rabeprazole (RA) sterile powder for injection, a rapid, sensitive and specific assay for quantitative determination of RA in dog plasma was developed and validated." | 1.33 | Liquid chromatographic/mass spectrometric assay of rabeprazole in dog plasma for a pharmacokinetic study. ( Feng, S; Guangji, W; Haitang, X; Hao, L; Jianguo, S; Jingwei, Z; Tian, L; Xiaoyan, Z, 2006) |
| " The proposed method was applied to the determination of rabeprazole in the tablet dosage form." | 1.32 | Voltammetric behaviour of rabeprazole at a glassy carbon electrode and its determination in tablet dosage form. ( Abd El-Ghany, N; Radi, A; Wahdan, T, 2004) |
| "Rabeprazole was stable in human plasma for 4 months at -70 +/- 5 degrees C and for 20." | 1.32 | Direct injection, column switching-liquid chromatographic technique for the estimation of rabeprazole in bioequivalence study. ( Gupta, S; Jain, M; Lohray, BB; Shah, H; Shah, R; Singh, SS; Thakker, P, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (72.00) | 29.6817 |
| 2010's | 7 (28.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, LN | 1 |
| Shen, YW | 1 |
| Ying, YW | 1 |
| Li, D | 1 |
| Li, TF | 1 |
| Zhang, XH | 1 |
| Zhao, P | 1 |
| Ding, L | 2 |
| Wang, YQ | 1 |
| Shah, P | 1 |
| Singh, MH | 1 |
| Yang, YX | 1 |
| Metz, DC | 1 |
| Lu, C | 1 |
| Jia, Y | 1 |
| Song, Y | 1 |
| Li, X | 1 |
| Sun, Y | 1 |
| Zhao, J | 1 |
| Wang, S | 1 |
| Shi, L | 1 |
| Wen, A | 1 |
| Hishinuma, T | 1 |
| Suzuki, K | 1 |
| Yamaguchi, H | 1 |
| Yamagishi, H | 1 |
| Koike, T | 1 |
| Ohara, S | 1 |
| Shimosegawa, T | 1 |
| Mano, N | 1 |
| Goto, J | 1 |
| Garrean, CP | 1 |
| Zhang, Q | 1 |
| Gonsalves, N | 1 |
| Hirano, I | 1 |
| Bharathi, DV | 1 |
| Hotha, KK | 1 |
| Jagadeesh, B | 1 |
| Chatki, PK | 1 |
| Thriveni, K | 1 |
| Mullangi, R | 1 |
| Naidu, A | 1 |
| Kim, JH | 1 |
| Sinn, DH | 1 |
| Son, HJ | 1 |
| Kim, JJ | 1 |
| Rhee, JC | 1 |
| Rhee, PL | 1 |
| Wu, JC | 1 |
| Xiao, YL | 1 |
| Peng, S | 1 |
| Tao, J | 1 |
| Wang, AJ | 1 |
| Lin, JK | 1 |
| Hu, PJ | 1 |
| Chen, MH | 1 |
| Molina-Infante, J | 1 |
| Ferrando-Lamana, L | 1 |
| Ripoll, C | 1 |
| Hernandez-Alonso, M | 1 |
| Mateos, JM | 1 |
| Fernandez-Bermejo, M | 1 |
| Dueñas, C | 1 |
| Fernandez-Gonzalez, N | 1 |
| Quintana, EM | 1 |
| Gonzalez-Nuñez, MA | 1 |
| Chitlange, SS | 1 |
| Mulla, AI | 1 |
| Pawbake, GR | 1 |
| Wankhede, SB | 1 |
| Nishizawa, T | 1 |
| Suzuki, H | 1 |
| Maekawa, T | 1 |
| Harada, N | 1 |
| Toyokawa, T | 1 |
| Kuwai, T | 1 |
| Ohara, M | 1 |
| Suzuki, T | 1 |
| Kawanishi, M | 1 |
| Noguchi, K | 1 |
| Yoshio, T | 1 |
| Katsushima, S | 1 |
| Tsuruta, H | 1 |
| Masuda, E | 1 |
| Tanaka, M | 1 |
| Katayama, S | 1 |
| Kawamura, N | 1 |
| Nishizawa, Y | 1 |
| Hibi, T | 1 |
| Takahashi, M | 1 |
| Kawai, T | 1 |
| Kawakami, K | 1 |
| Kudo, T | 1 |
| Ogiahara, S | 1 |
| Handa, Y | 1 |
| Moriyasu, F | 1 |
| Skoczylas, T | 1 |
| Sarosiek, I | 1 |
| Sostarich, S | 1 |
| McElhinney, C | 1 |
| Durham, S | 1 |
| Sarosiek, J | 1 |
| Gardner, JD | 1 |
| Sloan, S | 1 |
| Miner, PB | 1 |
| Robinson, M | 1 |
| Radi, A | 1 |
| Abd El-Ghany, N | 1 |
| Wahdan, T | 1 |
| Singh, SS | 1 |
| Jain, M | 1 |
| Shah, H | 1 |
| Gupta, S | 1 |
| Thakker, P | 1 |
| Shah, R | 1 |
| Lohray, BB | 1 |
| Ramakrishna, NV | 1 |
| Vishwottam, KN | 1 |
| Wishu, S | 1 |
| Koteshwara, M | 1 |
| Kumar, SS | 1 |
| Huang, J | 1 |
| Xu, Y | 1 |
| Gao, S | 1 |
| Rui, L | 1 |
| Guo, Q | 1 |
| Dickman, R | 1 |
| Emmons, S | 1 |
| Cui, H | 1 |
| Sewell, J | 1 |
| Hernández, D | 1 |
| Esquivel, RF | 1 |
| Fass, R | 1 |
| Garcia, CV | 1 |
| Paim, CS | 1 |
| Steppe, M | 1 |
| Schapoval, EE | 1 |
| des Varannes, SB | 1 |
| Sacher-Huvelin, S | 1 |
| Vavasseur, F | 1 |
| Masliah, C | 1 |
| Le Rhun, M | 1 |
| Aygalenq, P | 1 |
| Bonnot-Marlier, S | 1 |
| Lequeux, Y | 1 |
| Galmiche, JP | 1 |
| Feng, S | 1 |
| Guangji, W | 1 |
| Jianguo, S | 1 |
| Haitang, X | 1 |
| Hao, L | 1 |
| Tian, L | 1 |
| Xiaoyan, Z | 1 |
| Jingwei, Z | 1 |
| Lee, YC | 1 |
| Lin, JT | 1 |
| Wang, HP | 1 |
| Chiu, HM | 1 |
| Wu, MS | 1 |
| Fan, YH | 1 |
| Lü, B | 1 |
| Zhan, LX | 1 |
| Zhang, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)[NCT04149470] | Phase 4 | 90 participants (Anticipated) | Interventional | 2020-10-07 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 trials available for rabeprazole and Sensitivity and Specificity
| Article | Year |
|---|---|
Comparison of one-week and two-week empirical trial with a high-dose rabeprazole in non-cardiac chest pain patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Chest Pain; Drug Administration Schedule; Empi | 2009 |
Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Analysis of Variance; Benzimidazoles; Cross-Over Stu | 2003 |
Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro-oesophageal reflux disease treated with a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Gast | 2003 |
The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Chest Pain; | 2005 |
Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth | 2006 |
Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Aryl Hyd | 2007 |
[Oesophageal acid exposure test in non-erosive gastroesophageal reflux disease and the diagnostic value of rabeprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Esophagus; Female; Gastric Acid; | 2007 |
18 other studies available for rabeprazole and Sensitivity and Specificity
| Article | Year |
|---|---|
Stereoselective pharmacokinetics of (R)-(+)- and (S)-(-)-rabeprazole in human using chiral LC-MS/MS after administration of rabeprazole sodium enteric-coated tablet.
Topics: Administration, Oral; Adolescent; Adult; Calibration; Chromatography, Liquid; Drug Stability; Humans | 2018 |
Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome.
Topics: Achlorhydria; Adolescent; Adult; Aged; Anti-Ulcer Agents; Esomeprazole; False Positive Reactions; Fe | 2013 |
Application of a liquid chromatographic/tandem mass spectrometric method to a urinary excretion study of rabeprazole and two of its metabolites in healthy human urine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, Liquid; Drug Stability; Female; Humans; Lin | 2015 |
Simple quantification of lansoprazole and rabeprazole concentrations in human serum by liquid chromatography/tandem mass spectrometry.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, Liquid; Humans; Lansoprazole; Male; Rabepra | 2008 |
Acid reflux detection and symptom-reflux association using 4-day wireless pH recording combining 48-hour periods off and on PPI therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Esophageal pH Monitoring; F | 2008 |
Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, High Pressure Liquid; Drug Stability; Human | 2009 |
Is longer duration of proton pump inhibitor trial better for gastroesophageal reflux disease-related non-cardiac chest pain?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chest Pain; Clinical Trials as Topic; Drug Administration S | 2009 |
Prevalence and symptom pattern of pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome III criteria.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Chi-Square Distribution; Dyspepsia | 2010 |
Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Bi | 2011 |
Stability-indicating TLC-densitometric method for estimation of dexrabeprazole and domperidone in pharmaceutical dosage form.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, Thin Layer; Densitometry; Domperidone; Dosa | 2010 |
Dual therapy for third-line Helicobacter pylori eradication and urea breath test prediction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2012 |
A new serum antibody test kit (E plate) for evaluation of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 2002 |
Voltammetric behaviour of rabeprazole at a glassy carbon electrode and its determination in tablet dosage form.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Carbon; Chromatography, High Pressure Liqui | 2004 |
Direct injection, column switching-liquid chromatographic technique for the estimation of rabeprazole in bioequivalence study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Calibration; Chromatography, High Pressure | 2004 |
High-performance liquid chromatography method for the quantification of rabeprazole in human plasma using solid-phase extraction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Chromatography, High Pressure Liquid; Drug | 2005 |
Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of rabeprazole in human plasma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Calibration; Carbohydrate Sequence; Chromat | 2005 |
Development and validation of a dissolution test for rabeprazole sodium in coated tablets.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Chromatography, High Pressure Liquid; Hydro | 2006 |
Liquid chromatographic/mass spectrometric assay of rabeprazole in dog plasma for a pharmacokinetic study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Chromatography, Liquid; Dogs; Drug Stability; Rabe | 2006 |